Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2694-2701
Published online before print November 26, 2007, doi: 10.1161/CIRCULATIONAHA.107.719005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/23/2694    most recent
CIRCULATIONAHA.107.719005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow patientINFORMation
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khaw, K.-T.
Right arrow Articles by Day, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khaw, K.-T.
Right arrow Articles by Day, N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cancer
Hazardous Substances DB
*TESTOSTERONE
Related Collections
Right arrow Risk Factors
Right arrow Epidemiology

(Circulation. 2007;116:2694-2701.)
© 2007 American Heart Association, Inc.


Epidemiology

Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men

European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study

Kay-Tee Khaw, MBBChir, FRCP; Mitch Dowsett, PhD; Elizabeth Folkerd, PhD; Sheila Bingham, PhD; Nicholas Wareham, MBBS, PhD; Robert Luben, BSc; Ailsa Welch, PhD; Nicholas Day, PhD

From the Department of Public Health and Primary Care (K.-T.K., R.L., A.W., N.D.), Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK; Academic Department of Biochemistry (M.D., E.F.), Royal Marsden Hospital, London, UK; and MRC Dunn Human Nutrition Unit (S.B.) and MRC Epidemiology Unit (N.W.), Cambridge, UK.

Correspondence to Kay-Tee Khaw, Clinical Gerontology Unit Box 251, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK. E-mail kk101{at}medschl.cam.ac.uk

Received June 1, 2007; accepted September 11, 2007.

Background— The relation between endogenous testosterone concentrations and health in men is controversial.

Methods and Results— We examined the prospective relationship between endogenous testosterone concentrations and mortality due to all causes, cardiovascular disease, and cancer in a nested case-control study based on 11 606 men aged 40 to 79 years surveyed in 1993 to 1997 and followed up to 2003. Among those without prevalent cancer or cardiovascular disease, 825 men who subsequently died were compared with a control group of 1489 men still alive, matched for age and date of baseline visit. Endogenous testosterone concentrations at baseline were inversely related to mortality due to all causes (825 deaths), cardiovascular disease (369 deaths), and cancer (304 deaths). Odds ratios (95% confidence intervals) for mortality for increasing quartiles of endogenous testosterone compared with the lowest quartile were 0.75 (0.55 to 1.00), 0.62 (0.45 to 0.84), and 0.59 (0.42 to 0.85), respectively (P<0.001 for trend after adjustment for age, date of visit, body mass index, systolic blood pressure, blood cholesterol, cigarette smoking, diabetes mellitus, alcohol intake, physical activity, social class, education, dehydroepiandrosterone sulfate, androstanediol glucuronide, and sex hormone binding globulin). An increase of 6 nmol/L serum testosterone ({approx}1 SD) was associated with a 0.81 (95% confidence interval 0.71 to 0.92, P<0.01) multivariable-adjusted odds ratio for mortality. Inverse relationships were also observed for deaths due to cardiovascular causes and cancer and after the exclusion of deaths that occurred in the first 2 years.

Conclusions— In men, endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes. Low testosterone may be a predictive marker for those at high risk of cardiovascular disease.


 

CLINICAL PERSPECTIVE


Find additional patient-related information at:

http://www.americanheart.org/presenter.jhtml?identifier=3054559


This article has been cited by other articles:


Home page
J Gerontol B Psychol Sci Soc SciHome page
N. Gavrilova and S. T. Lindau
Salivary Sex Hormone Measurement in a National, Population-Based Study of Older Adults
J Gerontol B Psychol Sci Soc Sci, November 1, 2009; 64B(suppl_1): i94 - i105.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
B. B Yeap, S A P. Chubb, Z. Hyde, K. Jamrozik, G. J Hankey, L. Flicker, and P. E Norman
Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study
Eur. J. Endocrinol., October 1, 2009; 161(4): 591 - 598.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
G. I Hackett
Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes
The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 214 - 217.
[Abstract] [PDF]


Home page
Eur J EndocrinolHome page
T. Vikan, H. Schirmer, I. Njolstad, and J. Svartberg
Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study
Eur. J. Endocrinol., September 1, 2009; 161(3): 435 - 442.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Mathur, C. Malkin, B. Saeed, R Muthusamy, T H. Jones, and K. Channer
Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men
Eur. J. Endocrinol., September 1, 2009; 161(3): 443 - 449.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
A. M. Traish, F. Saad, R. J. Feeley, and A. Guay
The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease
J Androl, September 1, 2009; 30(5): 477 - 494.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc GenetHome page
A. Q. Reuwer, M. T. Twickler, B. A. Hutten, F. W. Molema, N. J. Wareham, G. M. Dallinga-Thie, R. L. Bogorad, V. Goffin, M. Smink-Bol, J. J.P. Kastelein, et al.
Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
Circ Cardiovasc Genet, August 1, 2009; 2(4): 389 - 395.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. B. Yeap, Z. Hyde, O. P. Almeida, P. E. Norman, S. A. P. Chubb, K. Jamrozik, L. Flicker, and G. J. Hankey
Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2353 - 2359.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Tivesten, L. Vandenput, F. Labrie, M. K. Karlsson, O. Ljunggren, D. Mellstrom, and C. Ohlsson
Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2482 - 2488.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. Svartberg, S. K Braekkan, G. A Laughlin, and J.-B. Hansen
Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study
Eur. J. Endocrinol., May 1, 2009; 160(5): 833 - 838.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. L. Tharp, I. Masseau, J. Ivey, V. K. Ganjam, and D. K. Bowles
Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine
Cardiovasc Res, April 1, 2009; 82(1): 152 - 160.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. J. Carrero, A. R. Qureshi, P. Parini, S. Arver, B. Lindholm, P. Barany, O. Heimburger, and P. Stenvinkel
Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients
J. Am. Soc. Nephrol., March 1, 2009; 20(3): 613 - 620.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
T H. Jones
Late onset hypogonadism
BMJ, February 13, 2009; 338(feb13_1): b352 - b352.
[Full Text]


Home page
ESC Textbook of Cardiovascular MedicineHome page
G. Jackson
CHAPTER 15c Erectile Dysfunction
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text]


Home page
Eur J EndocrinolHome page
B Lapauw, S Goemaere, H Zmierczak, I Van Pottelbergh, A Mahmoud, Y Taes, D De Bacquer, S Vansteelandt, and J M Kaufman
The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes
Eur. J. Endocrinol., October 1, 2008; 159(4): 459 - 468.
[Abstract] [Full Text] [PDF]


Home page
InnovAiTHome page
C. Simon
Testosterone deficiency--the male menopause?
InnovAiT, September 1, 2008; 1(9): 625 - 630.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. A. Platz
Low Testosterone and Risk of Premature Death in Older Men: Analytical and Preanalytical Issues in Measuring Circulating Testosterone
Clin. Chem., July 1, 2008; 54(7): 1110 - 1112.
[Full Text] [PDF]


Home page
CirculationHome page
S. Basaria and A. S. Dobs
Testosterone Making an Entry Into the Cardiometabolic World
Circulation, December 4, 2007; 116(23): 2658 - 2661.
[Full Text] [PDF]